Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7053 in advanced hematologic malignancies
NCT05983146Phase 1Withdrawn
- Sponsor
- Hengrui
- Start
- Sep 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of HRS-7053 in hematologic malignancy, sponsored by Hengrui. Primary endpoints: Incidence and severity of adverse events (AES) up to 3 years, Maximum tolerated dose up to 3 years and 1 more. Planned start Sep 2023; status: withdrawn.
02
Drugs
HRS-7053
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT05983146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983146.